CompletedPhase 2ketamine
A Study to Assess the Analgesic Properties of a Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction
Sponsored by Lotus Clinical Research, LLC
NCT ID
NCT02199678
Target Enrollment
120 participants
Start Date
2014-07
Est. Completion
2014-11
About This Study
This is a Phase 2, randomized, multicenter, parallel group, double-blind, dose-ranging, placebo-controlled evaluation of the analgesic efficacy, safety and pharmacokinetics of ketamine sublingual wafer in adult subjects who experience post operative pain after undergoing third molar extraction.
Conditions Studied
Interventions
- •Placebo
- •ketamine 25 mg
- •ketamine 35 mg
- •ketamine 50 mg
Eligibility
Age:18 Years - 38 Years
Healthy Volunteers:Yes
View full eligibility criteria
18- 38 years of age Scheduled to undergo two ipsilateral third molar extractions
Study Locations (2)
Lotus Clinical Research, LLC
Pasadena, California, United States
Prahealthsciences
Salt Lake City, Utah, United States